Predicting treatment response in metastatic breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial studies how well CT and PET scans can predict if a certain type of breast cancer will respond to a targeted treatment. It focuses on women who had a biopsy of the liver, lung, or chest lining after the cancer spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic breast cancer (cancer that has spread to other parts of the body)
- You had a biopsy (tissue sample taken) from your liver, lung, or the lining of your chest (pleura) between January 2005 and January 2024
- A CT scan or PET scan was done within 3 months before that biopsy, or before your last treatment was stopped
- Your cancer's HER2 status is known
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special type of PET scan can predict how well a targeted cancer drug (T-DXd) will work for patients with advanced breast cancer that has specific HER2 markers. The goal is to help doctors personalize treatment decisions based on imaging results.
This early-phase study uses a special PET scan with a drug tagged for imaging to predict how well HER2-targeted treatments will work. It may help doctors choose the most effective therapy for HER2-positive breast cancer.
This trial uses a special PET scan (HER2-PET) to see if a targeted drug (trastuzumab deruxtecan) works better for your type of metastatic breast cancer. The goal is to match the treatment to how much HER2 protein your tumors show.
This study tests whether using PET scans (a special imaging technique) to monitor how your HER2-positive breast cancer responds to treatment before surgery can help doctors choose the best treatment plan for you. The goal is to improve outcomes by personalizing therapy based on how your tumor responds.
This study uses special PET/MRI scans to see how well breast cancer treatments are working. It aims to find better ways to monitor your cancer and guide your care.
This study tests a new type of PET scan (a specialized imaging test) to see if it can predict whether chemotherapy will work for HER2-positive breast cancer before surgery. The scan uses a radioactive tracer designed to highlight HER2-positive cancer cells, helping doctors personalize your treatment plan.
Hear when a new Radiomics trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.